In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $53.77 in the last session, down -0.70% from day before closing price of $54.15. In other words, the price has decreased by -$0.70 from its previous closing price. On the day, 0.73 million shares were traded. CYTK stock price reached its highest trading level at $54.06 during the session, while it also had its lowest trading level at $52.85.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 09 ’24 when B LYNNE PARSHALL bought 5,000 shares for $54.92 per share.
PARSHALL B LYNNE sold 5,000 shares of CYTK for $274,600 on Sep 09 ’24. The Director now owns 20,600 shares after completing the transaction at $54.92 per share. On Sep 03 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 7,384 shares for $57.01 each. As a result, the insider received 420,973 and left with 122,920 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6326578176 and an Enterprise Value of 6059956736. For the stock, the TTM Price-to-Sale (P/S) ratio is 2021.27 while its Price-to-Book (P/B) ratio in mrq is 58.22. Its current Enterprise Value per Revenue stands at 1933.617 whereas that against EBITDA is -12.288.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -4.33%, while the 200-Day Moving Average is calculated to be -13.28%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 1.41M shares per day over the past 3-months and 1189450 shares per day over the past 10 days. A total of 117.66M shares are outstanding, with a floating share count of 113.74M. Insiders hold about 3.33% of the company’s shares, while institutions hold 113.93% stake in the company. Shares short for CYTK as of 1723680000 were 18634439 with a Short Ratio of 13.17, compared to 1721001600 on 17464893. Therefore, it implies a Short% of Shares Outstanding of 18634439 and a Short% of Float of 24.200001.
